A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
Gilles Salles(Memorial Sloan Kettering Cancer Center), Paolo Ghia(Vita-Salute San Raffaele University), Bipinkumar Amin(Bristol-Myers Squibb (Switzerland)), Adeboye H. Adewoye(Amgen (United States)), Muhammad-Ali A. Zaydan, Nashat Gabrail(Gabrail Cancer Center), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Michelle Wong(University of British Columbia)
Cited by 10
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890